Sezary Syndrome (SS) - Market Insights, Epidemiology and Market Forecast-2028
This report can be delivered to the clients within 24 Hours
DelveInsight’s ‘Sezary Syndrome (SS) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Sezary Syndrome (SS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Sezary Syndrome (SS) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Sezary Syndrome (SS) - Disease Understanding and Treatment Algorithm
Sezary Syndrome (SS) is generally defined as the triad of erythroderma, generalized lymphadenopathy and the presence of clonally related neoplastic T-cells with cerebriform nuclei (Sezary cells) in skin, lymph nodes and peripheral blood. It was first recognized as a separate clinical condition in the year 1938 and can be defined as the T-cell lymphoma of the skin and peripheral blood. Although Sezary Syndrome was initially identified as a separate variant of Mycosis Fungoides (MF), the recent WHO-EORTC combined classification scheme categorizes these two indications as different clinical entities with distinctive and characteristic clinical features.
The DelveInsight Sezary Syndrome (SS) market report gives a thorough understanding of the Sezary Syndrome (SS) by including details such as disease definition, staging, causes, clinical features, immunophenotype, histopathology, pathogenesis, genetic features, symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Sezary Syndrome (SS) in the United States and Europe.
Sezary Syndrome (SS) Epidemiology
The Sezary Syndrome (SS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by incident population, gender-specific incidence population and stage specific incidence cases of Sezary Syndrome (SS).
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total incident population of Sezary Syndrome (SS) was estimated to be 429 [7MM] in 2018. United States accounts for the highest Sezary Syndrome (SS) cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest prevalent patient population of Sezary Syndrome (SS), followed by Germany.
Sezary Syndrome (SS) Drug Chapters
This segment of the Sezary Syndrome (SS) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently limited approved therapies including Shionogi’s Imunomax and Kyowa Kirin’s Poteligeo which are being used for the treatment of Sezary Syndrome (SS). However these drugs have shown to be effective in managing the Sezary Syndrome (SS). As Sezary Syndrome is is an aggressive subtype of cutaneous T cell lymphoma that presents with erythroderma plus circulating malignant T lymphocytes (Sйzary cells), with or without lymph node and/or visceral organ involvement and is also closely related to mycosis fungoides (MF). As there is no cure available for CTCL and the available treatments are for management of CTCL. The patients are treated with consecutive therapies until loss of response or without treatment ‘expectant therapy’ if no suitable therapy is available.
Sezary Syndrome (SS) Market Outlook
The Sezary Syndrome (SS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Sezary Syndrome (SS) is estimated to change during the forecasted period 2019-2028. It is estimated that the United States accounts for the largest market size of Sezary Syndrome (SS), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan in 2018.
The dynamics of Sezary Syndrome (SS) market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Sezary Syndrome (SS). Upcoming therapies such as Medivir’s Remetinostat, Elorac’s Naloxone Hydrochloride and many more, have the potential to create a significant positive shift in the Sezary Syndrome (SS) market size. The United States accounts for the largest market size of Sezary Syndrome (SS), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Sezary Syndrome (SS) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Sezary Syndrome (SS) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Sezary Syndrome (SS), several companies are working robustly on developing new therapies with novel mechanism of action.
Sezary Syndrome (SS) Report Insights
DelveInsight’s ‘Sezary Syndrome (SS) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Sezary Syndrome (SS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Sezary Syndrome (SS) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Sezary Syndrome (SS) - Disease Understanding and Treatment Algorithm
Sezary Syndrome (SS) is generally defined as the triad of erythroderma, generalized lymphadenopathy and the presence of clonally related neoplastic T-cells with cerebriform nuclei (Sezary cells) in skin, lymph nodes and peripheral blood. It was first recognized as a separate clinical condition in the year 1938 and can be defined as the T-cell lymphoma of the skin and peripheral blood. Although Sezary Syndrome was initially identified as a separate variant of Mycosis Fungoides (MF), the recent WHO-EORTC combined classification scheme categorizes these two indications as different clinical entities with distinctive and characteristic clinical features.
The DelveInsight Sezary Syndrome (SS) market report gives a thorough understanding of the Sezary Syndrome (SS) by including details such as disease definition, staging, causes, clinical features, immunophenotype, histopathology, pathogenesis, genetic features, symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Sezary Syndrome (SS) in the United States and Europe.
Sezary Syndrome (SS) Epidemiology
The Sezary Syndrome (SS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by incident population, gender-specific incidence population and stage specific incidence cases of Sezary Syndrome (SS).
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total incident population of Sezary Syndrome (SS) was estimated to be 429 [7MM] in 2018. United States accounts for the highest Sezary Syndrome (SS) cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest prevalent patient population of Sezary Syndrome (SS), followed by Germany.
Sezary Syndrome (SS) Drug Chapters
This segment of the Sezary Syndrome (SS) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently limited approved therapies including Shionogi’s Imunomax and Kyowa Kirin’s Poteligeo which are being used for the treatment of Sezary Syndrome (SS). However these drugs have shown to be effective in managing the Sezary Syndrome (SS). As Sezary Syndrome is is an aggressive subtype of cutaneous T cell lymphoma that presents with erythroderma plus circulating malignant T lymphocytes (Sйzary cells), with or without lymph node and/or visceral organ involvement and is also closely related to mycosis fungoides (MF). As there is no cure available for CTCL and the available treatments are for management of CTCL. The patients are treated with consecutive therapies until loss of response or without treatment ‘expectant therapy’ if no suitable therapy is available.
Sezary Syndrome (SS) Market Outlook
The Sezary Syndrome (SS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Sezary Syndrome (SS) is estimated to change during the forecasted period 2019-2028. It is estimated that the United States accounts for the largest market size of Sezary Syndrome (SS), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan in 2018.
The dynamics of Sezary Syndrome (SS) market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Sezary Syndrome (SS). Upcoming therapies such as Medivir’s Remetinostat, Elorac’s Naloxone Hydrochloride and many more, have the potential to create a significant positive shift in the Sezary Syndrome (SS) market size. The United States accounts for the largest market size of Sezary Syndrome (SS), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Sezary Syndrome (SS) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Sezary Syndrome (SS) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Sezary Syndrome (SS), several companies are working robustly on developing new therapies with novel mechanism of action.
Sezary Syndrome (SS) Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Sezary Syndrome (SS) market.
- Organize sales and marketing efforts by identifying the best opportunities for Sezary Syndrome (SS) market.
- To understand the future market competition in the Sezary Syndrome (SS) market.
1 KEY INSIGHTS
2 SEZARY SYNDROME (SS): MARKET OVERVIEW AT A GLANCE
2.1 Total Market Share (%) Distribution of Sezary Syndrome (SS) in 2016
2.2 Total Market Share (%) Distribution of Sezary Syndrome (SS) in 2027
3 DISEASE BACKGROUND AND OVERVIEW: SEZARY SYNDROME (SS)
3.1 Introduction
3.2 Staging
3.3 Causes
3.4 Clinical Features
3.4.1 Immunophenotype
3.4.2 Histopathology
3.4.3 Pathogenesis
3.4.4 Genetic Features
3.5 Symptoms
3.6 Diagnosis
4 EPIDEMIOLOGY AND PATIENT POPULATION
4.1 Key Findings
5 INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN 7MM
6 COUNTRY WISE-EPIDEMIOLOGY OF SEZARY SYNDROME (SS)
6.1 United States
6.1.1 Incident Population of Sйzary Syndrome (SS) in the United States
6.1.2 Gender Specific Incidence of SS in the United States
6.1.3 Stage-Specific Incidence of Sйzary Syndrome (SS) in the United States
6.2 EU5 Countries
6.3 Germany
6.3.1 Incident Population of SS in Germany
6.3.2 Gender Specific Incidence of SS in Germany
6.3.3 Stage-Specific Incidence of SS in Germany
6.4 France
6.4.1 Incident Population of SS in France
6.4.2 Gender Specific Incidence of SS in France
6.4.3 Stage-Specific Incidence of SS in France
6.5 Italy
6.5.1 Incident Population of SS in Italy
6.5.2 Gender Specific Incidence of SS in Italy
6.5.3 Stage-Specific Incidence of SS in Italy
6.6 Spain
6.6.1 Incident Population of SS in Spain
6.6.2 Gender Specific Incidence of SS in Spain
6.6.3 Stage-Specific Incidence of SS in Spain
6.7 The United Kingdom
6.7.1 Incident Population of SS in the United Kingdom
6.7.2 Gender Specific Incidence of SS in the United Kingdom
6.7.3 Stage-Specific Incidence of SS in the United Kingdom
6.8 Japan
6.8.1 Incident Population of SS in Japan
6.8.2 Gender Specific Incidence of SS in Japan
6.8.3 Stage-Specific Incidence of SS in Japan
7 TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
7.1 International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
7.2 United States
7.2.1 NCCN Guidelines
7.3 Europe
7.3.1 ESMO Guidelines
7.3.2 Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
7.3.3 EORTC recommendations for the treatment of mycosis fungoides/Seґzary syndrome
8 UNMET NEEDS
9 MARKETED DRUGS
9.1 Imunomax: Shionogi
9.1.1 Drug Description
9.1.2 Mechanism of Action:
9.1.3 Regulatory Milestones
9.1.4 Advantages and Disadvantages
9.1.5 Safety and Efficacy
9.1.6 Advantages & Disadvantages
9.1.7 Product Profile
9.2 Potelegio (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
9.2.1 Drug Description
9.2.2 Mechanism of Action
9.2.3 Regulatory Milestones
9.2.4 Advantages & Disadvantages
9.2.5 Safety and Efficacy
9.2.6 Product Profile
To be continued in report…
10 EMERGING THERAPIES
10.3 Remetinostat: Medivir AB
10.3.1 Product Description
10.3.2 Regulatory Milestones
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile
10.4 Naloxone Hydrochloride: Elorac
10.4.1 Product Description
10.4.2 Regulatory Milestones
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
11 SEZARY SYNDROME (MF): 7 MAJOR MARKET ANALYSIS
11.1 Key Findings
11.2 Total Market Size of Sezary Syndrome (SS) in 7MM
12 THE UNITED STATES MARKET OUTLOOK
12.1 United States Market Size
12.1.1 Total Market size of Sezary Syndrome (SS) in the United States
12.1.2 Late Stage Market Size of SS by First Line of Therapies in the United States
12.1.3 Late Stage Market Size of SS by Second Line of Therapies in the United States
13 EU-5 COUNTRIES: MARKET OUTLOOK
13.1 Germany
13.1.1 Total Market size of Sezary Syndrome in Germany
13.1.2 Late Stage Market Size of SS by First Line of Therapies in Germany
13.1.3 Late Stage Market Size of SS by Second Line of Therapies in Germany
13.2 France
13.2.1 Total Market size of Sezary Syndrome (SS) in France
13.2.2 Late Stage Market Size of SS by First Line of Therapies in France
13.2.3 Late Stage Market Size of SS by Second Line of Therapies in France
13.3 Italy
13.3.1 Total Market size of Sezary Syndrome (SS) in Italy
13.3.2 Late Stage Market Size of SS by First Line of Therapies in Italy
13.3.3 Late Stage Market Size of SS by Second Line of Therapies in Italy
13.4 Spain
13.4.1 Total Market size of Sezary Syndrome (SS) in Spain
13.4.2 Late Stage Market Size of SS by First Line of Therapies in Spain
13.4.3 Late Stage Market Size of SS by Second Line of Therapies in Spain
13.5 United Kingdom
13.5.1 Total Market size of Sezary Syndrome (SS) in UK
13.5.2 Late Stage Market Size of SS by First Line of Therapies in UK
13.5.3 Late Stage Market Size of SS by Second Line of Therapies in UK
13.6 Japan: Market Outlook
13.6.1 Total Market size of Sezary Syndrome (SS) in Japan
13.6.2 Late Stage Market Size of SS by First Line of Therapies in Japan
13.6.3 Late Stage Market Size of SS by Second Line of Therapies in Japan
14 MARKET DRIVERS
15 MARKET BARRIERS
16 APPENDIX
17 REPORT METHODOLOGY
17.1 Sources Used
18 DELVEINSIGHT CAPABILITIES
19 DISCLAIMER
20 ABOUT DELVEINSIGHT
2 SEZARY SYNDROME (SS): MARKET OVERVIEW AT A GLANCE
2.1 Total Market Share (%) Distribution of Sezary Syndrome (SS) in 2016
2.2 Total Market Share (%) Distribution of Sezary Syndrome (SS) in 2027
3 DISEASE BACKGROUND AND OVERVIEW: SEZARY SYNDROME (SS)
3.1 Introduction
3.2 Staging
3.3 Causes
3.4 Clinical Features
3.4.1 Immunophenotype
3.4.2 Histopathology
3.4.3 Pathogenesis
3.4.4 Genetic Features
3.5 Symptoms
3.6 Diagnosis
4 EPIDEMIOLOGY AND PATIENT POPULATION
4.1 Key Findings
5 INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN 7MM
6 COUNTRY WISE-EPIDEMIOLOGY OF SEZARY SYNDROME (SS)
6.1 United States
6.1.1 Incident Population of Sйzary Syndrome (SS) in the United States
6.1.2 Gender Specific Incidence of SS in the United States
6.1.3 Stage-Specific Incidence of Sйzary Syndrome (SS) in the United States
6.2 EU5 Countries
6.3 Germany
6.3.1 Incident Population of SS in Germany
6.3.2 Gender Specific Incidence of SS in Germany
6.3.3 Stage-Specific Incidence of SS in Germany
6.4 France
6.4.1 Incident Population of SS in France
6.4.2 Gender Specific Incidence of SS in France
6.4.3 Stage-Specific Incidence of SS in France
6.5 Italy
6.5.1 Incident Population of SS in Italy
6.5.2 Gender Specific Incidence of SS in Italy
6.5.3 Stage-Specific Incidence of SS in Italy
6.6 Spain
6.6.1 Incident Population of SS in Spain
6.6.2 Gender Specific Incidence of SS in Spain
6.6.3 Stage-Specific Incidence of SS in Spain
6.7 The United Kingdom
6.7.1 Incident Population of SS in the United Kingdom
6.7.2 Gender Specific Incidence of SS in the United Kingdom
6.7.3 Stage-Specific Incidence of SS in the United Kingdom
6.8 Japan
6.8.1 Incident Population of SS in Japan
6.8.2 Gender Specific Incidence of SS in Japan
6.8.3 Stage-Specific Incidence of SS in Japan
7 TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
7.1 International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
7.2 United States
7.2.1 NCCN Guidelines
7.3 Europe
7.3.1 ESMO Guidelines
7.3.2 Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
7.3.3 EORTC recommendations for the treatment of mycosis fungoides/Seґzary syndrome
8 UNMET NEEDS
9 MARKETED DRUGS
9.1 Imunomax: Shionogi
9.1.1 Drug Description
9.1.2 Mechanism of Action:
9.1.3 Regulatory Milestones
9.1.4 Advantages and Disadvantages
9.1.5 Safety and Efficacy
9.1.6 Advantages & Disadvantages
9.1.7 Product Profile
9.2 Potelegio (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
9.2.1 Drug Description
9.2.2 Mechanism of Action
9.2.3 Regulatory Milestones
9.2.4 Advantages & Disadvantages
9.2.5 Safety and Efficacy
9.2.6 Product Profile
To be continued in report…
10 EMERGING THERAPIES
10.3 Remetinostat: Medivir AB
10.3.1 Product Description
10.3.2 Regulatory Milestones
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile
10.4 Naloxone Hydrochloride: Elorac
10.4.1 Product Description
10.4.2 Regulatory Milestones
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
11 SEZARY SYNDROME (MF): 7 MAJOR MARKET ANALYSIS
11.1 Key Findings
11.2 Total Market Size of Sezary Syndrome (SS) in 7MM
12 THE UNITED STATES MARKET OUTLOOK
12.1 United States Market Size
12.1.1 Total Market size of Sezary Syndrome (SS) in the United States
12.1.2 Late Stage Market Size of SS by First Line of Therapies in the United States
12.1.3 Late Stage Market Size of SS by Second Line of Therapies in the United States
13 EU-5 COUNTRIES: MARKET OUTLOOK
13.1 Germany
13.1.1 Total Market size of Sezary Syndrome in Germany
13.1.2 Late Stage Market Size of SS by First Line of Therapies in Germany
13.1.3 Late Stage Market Size of SS by Second Line of Therapies in Germany
13.2 France
13.2.1 Total Market size of Sezary Syndrome (SS) in France
13.2.2 Late Stage Market Size of SS by First Line of Therapies in France
13.2.3 Late Stage Market Size of SS by Second Line of Therapies in France
13.3 Italy
13.3.1 Total Market size of Sezary Syndrome (SS) in Italy
13.3.2 Late Stage Market Size of SS by First Line of Therapies in Italy
13.3.3 Late Stage Market Size of SS by Second Line of Therapies in Italy
13.4 Spain
13.4.1 Total Market size of Sezary Syndrome (SS) in Spain
13.4.2 Late Stage Market Size of SS by First Line of Therapies in Spain
13.4.3 Late Stage Market Size of SS by Second Line of Therapies in Spain
13.5 United Kingdom
13.5.1 Total Market size of Sezary Syndrome (SS) in UK
13.5.2 Late Stage Market Size of SS by First Line of Therapies in UK
13.5.3 Late Stage Market Size of SS by Second Line of Therapies in UK
13.6 Japan: Market Outlook
13.6.1 Total Market size of Sezary Syndrome (SS) in Japan
13.6.2 Late Stage Market Size of SS by First Line of Therapies in Japan
13.6.3 Late Stage Market Size of SS by Second Line of Therapies in Japan
14 MARKET DRIVERS
15 MARKET BARRIERS
16 APPENDIX
17 REPORT METHODOLOGY
17.1 Sources Used
18 DELVEINSIGHT CAPABILITIES
19 DISCLAIMER
20 ABOUT DELVEINSIGHT
LIST OF TABLES
TABLE 1: ISCL/EORTC REVISION TO THE CLASSIFICATION OF MF AND SS
TABLE 2: RECOMMENDED EVALUATION/INITIAL STAGING OF THE PATIENT WITH SЙZARY SYNDROME
TABLE 3: TOTAL INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN THE 7MM (2016-2027)
TABLE 4: INCIDENT POPULATION OF SЙZARY SYNDROME IN THE US (2016-2027)
TABLE 5: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE US (2016-2027)
TABLE 6: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME(SS) IN THE US (2016-2027)
TABLE 7: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
TABLE 8: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
TABLE 9: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
TABLE 10: INCIDENT POPULATION OF SЙZARY SYNDROME IN FRANCE (2016-2027)
TABLE 11: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
TABLE 12: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
TABLE 13: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN ITALY (2016-2027)
TABLE 14: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN ITALY (2016-2027)
TABLE 15: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME IN ITALY (2016-2027)
TABLE 16: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
TABLE 17: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
TABLE 18: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
TABLE 19: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
TABLE 20: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
TABLE 21: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
TABLE 22: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
TABLE 23: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
TABLE 24: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
TABLE 25 : RECOMMENDATIONS FOR TREATMENT OF SEZARY SYNDROME BY RADIATION THERAPY
TABLE 26: BAD GUIDELINES FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME
TABLE 27 : RECOMMENDATIONS FOR TREATMENT OF SEZARY SYNDROME STAGES
TABLE 28: 7 MAJOR MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 29: UNITED STATES MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 30: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 31: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 32: GERMANY MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 33: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 34: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 35: FRENCH MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 36: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 37: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 38: ITALIAN MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 39: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 40: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 41: SPANISH MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 42: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 43: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 44: UK MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 45: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 46: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 47: JAPANESE MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 48: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 50: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 1: ISCL/EORTC REVISION TO THE CLASSIFICATION OF MF AND SS
TABLE 2: RECOMMENDED EVALUATION/INITIAL STAGING OF THE PATIENT WITH SЙZARY SYNDROME
TABLE 3: TOTAL INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN THE 7MM (2016-2027)
TABLE 4: INCIDENT POPULATION OF SЙZARY SYNDROME IN THE US (2016-2027)
TABLE 5: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE US (2016-2027)
TABLE 6: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME(SS) IN THE US (2016-2027)
TABLE 7: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
TABLE 8: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
TABLE 9: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
TABLE 10: INCIDENT POPULATION OF SЙZARY SYNDROME IN FRANCE (2016-2027)
TABLE 11: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
TABLE 12: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
TABLE 13: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN ITALY (2016-2027)
TABLE 14: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN ITALY (2016-2027)
TABLE 15: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME IN ITALY (2016-2027)
TABLE 16: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
TABLE 17: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
TABLE 18: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
TABLE 19: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
TABLE 20: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
TABLE 21: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
TABLE 22: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
TABLE 23: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
TABLE 24: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
TABLE 25 : RECOMMENDATIONS FOR TREATMENT OF SEZARY SYNDROME BY RADIATION THERAPY
TABLE 26: BAD GUIDELINES FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME
TABLE 27 : RECOMMENDATIONS FOR TREATMENT OF SEZARY SYNDROME STAGES
TABLE 28: 7 MAJOR MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 29: UNITED STATES MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 30: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 31: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 32: GERMANY MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 33: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 34: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 35: FRENCH MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 36: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 37: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 38: ITALIAN MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 39: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 40: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 41: SPANISH MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 42: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 43: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 44: UK MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 45: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 46: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 47: JAPANESE MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
TABLE 48: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 50: LATE STAGE MARKET SIZE OF SEZARY SYNDROME BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
LIST OF FIGURES
FIGURE 1: STAGING OF CUTANEOUS T-CELL LYMPHOMA (MF/SS): TNMB CLASSIFICATION
FIGURE 2: PATHOGENESIS OF MYCOSIS FUNGOIDES
FIGURE 3: TOTAL INCIDENT PATIENT POPULATION OF SEZARY SYNDROME (SS) IN THE 7MM (2016-2027)
FIGURE 4: INCIDENT POPULATION OF SЙZARY SYNDROME (SS) IN THE US (2016-2027)
FIGURE 5: GENDER SPECIFIC INCIDENCE OF SЙZARY SYNDROME (SS) IN THE US (2016-2027)
FIGURE 6: STAGE-SPECIFIC INCIDENCE OF SЙZARY SYNDROME (SS) IN THE US (2016-2027)
FIGURE 7: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
FIGURE 8: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
FIGURE 9: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
FIGURE 10: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
FIGURE 11: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
FIGURE 12: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
FIGURE 13: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN ITALY (2016-2027)
FIGURE 14: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN ITALY (2016-2027)
FIGURE 15: STAGE-SPECIFIC INCIDENCE OF SЙZARY SYNDROME IN ITALY (2016-2027)
FIGURE 16: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
FIGURE 17: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
FIGURE 18: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
FIGURE 19: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
FIGURE 20: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
FIGURE 21: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
FIGURE 22: INCIDENT POPULATION OF SЙZARY SYNDROME IN JAPAN (2016-2027)
FIGURE 23: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
FIGURE 24: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
FIGURE 25: TREATMENT ALGORITHM OF MYCOSIS FUNGOIDES
FIGURE 26: TREATMENT ALGORITHM OF SEZARY SYNDROME (SS)
FIGURE 27:TREATMENT FOR STAGE IA OF SEZARY SYNDROME (SS)
FIGURE 28:TREATMENT FOR STAGE IB-IIA OF SEZARY SYNDROME (SS)
FIGURE 29:TREATMENT FOR STAGE IIB OF SEZARY SYNDROME (SS)
FIGURE 30:TREATMENT FOR STAGE III OF SEZARY SYNDROME (SS)
FIGURE 31:TREATMENT FOR STAGE IV OF SEZARY SYNDROME (SS)
FIGURE 32:TREATMENT FOR PRIMARY CUTANEOUS CD30+ T-CELL LYMPHOPROLIFERATIVE DISORDERS
FIGURE 33:TREATMENT FOR LYMPHOMATOID PAPULOSIS
FIGURE 34: UNMET NEEDS OF SEZARY SYNDROME (SS)
FIGURE 35: 7 MAJOR MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
FIGURE 36: MARKET SIZE OF SEZARY SYNDROME (SS) IN THE UNITED STATES, USD MILLIONS (2016-2027)
FIGURE 37: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME SS BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 38: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 39: MARKET SIZE OF SEZARY SYNDROME IN GERMANY, USD MILLIONS (2016-2027)
FIGURE 40: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 41: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 42: MARKET SIZE OF SEZARY SYNDROME (SS) IN FRANCE, USD MILLIONS (2016-2027)
FIGURE 43: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 44: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 45: MARKET SIZE OF SEZARY SYNDROME (SS) IN ITALY, USD MILLIONS (2016-2027)
FIGURE 46: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 47: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 48: MARKET SIZE OF SEZARY SYNDROME (SS) IN SPAIN, USD MILLIONS (2016-2027)
FIGURE 49: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 50: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 51: MARKET SIZE OF SEZARY SYNDROME (SS) IN UK, USD MILLIONS (2016-2027)
FIGURE 52: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 53: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 54: MARKET SIZE OF SEZARY SYNDROME (SS) IN JAPAN, USD MILLIONS (2016-2027)
FIGURE 55: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 56: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 57: MARKET DRIVERS
FIGURE 58: MARKET BARRIERS
FIGURE 1: STAGING OF CUTANEOUS T-CELL LYMPHOMA (MF/SS): TNMB CLASSIFICATION
FIGURE 2: PATHOGENESIS OF MYCOSIS FUNGOIDES
FIGURE 3: TOTAL INCIDENT PATIENT POPULATION OF SEZARY SYNDROME (SS) IN THE 7MM (2016-2027)
FIGURE 4: INCIDENT POPULATION OF SЙZARY SYNDROME (SS) IN THE US (2016-2027)
FIGURE 5: GENDER SPECIFIC INCIDENCE OF SЙZARY SYNDROME (SS) IN THE US (2016-2027)
FIGURE 6: STAGE-SPECIFIC INCIDENCE OF SЙZARY SYNDROME (SS) IN THE US (2016-2027)
FIGURE 7: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
FIGURE 8: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
FIGURE 9: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN GERMANY (2016-2027)
FIGURE 10: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
FIGURE 11: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
FIGURE 12: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN FRANCE (2016-2027)
FIGURE 13: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN ITALY (2016-2027)
FIGURE 14: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN ITALY (2016-2027)
FIGURE 15: STAGE-SPECIFIC INCIDENCE OF SЙZARY SYNDROME IN ITALY (2016-2027)
FIGURE 16: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
FIGURE 17: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
FIGURE 18: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN SPAIN (2016-2027)
FIGURE 19: INCIDENT POPULATION OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
FIGURE 20: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
FIGURE 21: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN THE UK (2016-2027)
FIGURE 22: INCIDENT POPULATION OF SЙZARY SYNDROME IN JAPAN (2016-2027)
FIGURE 23: GENDER SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
FIGURE 24: STAGE-SPECIFIC INCIDENCE OF SEZARY SYNDROME (SS) IN JAPAN (2016-2027)
FIGURE 25: TREATMENT ALGORITHM OF MYCOSIS FUNGOIDES
FIGURE 26: TREATMENT ALGORITHM OF SEZARY SYNDROME (SS)
FIGURE 27:TREATMENT FOR STAGE IA OF SEZARY SYNDROME (SS)
FIGURE 28:TREATMENT FOR STAGE IB-IIA OF SEZARY SYNDROME (SS)
FIGURE 29:TREATMENT FOR STAGE IIB OF SEZARY SYNDROME (SS)
FIGURE 30:TREATMENT FOR STAGE III OF SEZARY SYNDROME (SS)
FIGURE 31:TREATMENT FOR STAGE IV OF SEZARY SYNDROME (SS)
FIGURE 32:TREATMENT FOR PRIMARY CUTANEOUS CD30+ T-CELL LYMPHOPROLIFERATIVE DISORDERS
FIGURE 33:TREATMENT FOR LYMPHOMATOID PAPULOSIS
FIGURE 34: UNMET NEEDS OF SEZARY SYNDROME (SS)
FIGURE 35: 7 MAJOR MARKET SIZE OF SEZARY SYNDROME (SS) IN USD MILLION (2016-2027)
FIGURE 36: MARKET SIZE OF SEZARY SYNDROME (SS) IN THE UNITED STATES, USD MILLIONS (2016-2027)
FIGURE 37: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME SS BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 38: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 39: MARKET SIZE OF SEZARY SYNDROME IN GERMANY, USD MILLIONS (2016-2027)
FIGURE 40: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 41: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 42: MARKET SIZE OF SEZARY SYNDROME (SS) IN FRANCE, USD MILLIONS (2016-2027)
FIGURE 43: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 44: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 45: MARKET SIZE OF SEZARY SYNDROME (SS) IN ITALY, USD MILLIONS (2016-2027)
FIGURE 46: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 47: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 48: MARKET SIZE OF SEZARY SYNDROME (SS) IN SPAIN, USD MILLIONS (2016-2027)
FIGURE 49: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 50: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 51: MARKET SIZE OF SEZARY SYNDROME (SS) IN UK, USD MILLIONS (2016-2027)
FIGURE 52: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 53: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 54: MARKET SIZE OF SEZARY SYNDROME (SS) IN JAPAN, USD MILLIONS (2016-2027)
FIGURE 55: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 56: LATE STAGE MARKET SIZE OF SЙZARY SYNDROME BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 57: MARKET DRIVERS
FIGURE 58: MARKET BARRIERS
